For decades, hospitals and pathology laboratories have preserved human tissue by immersing it in formalin, a solution based on formaldehyde, and embedding it in paraffin wax. The process stabilizes tissue so that it can be sliced into extremely thin sections, stained and examined under a microscope. This routine has created vast archives containing samples from patients with cancer, inflammatory disease and many other conditions. In many cases, the clinical histories and treatment outcomes of those patients are also known, making the archives potentially invaluable for researchers seeking biological explanations for disease progression or differences in treatment response.

The challenge is that formalin preservation can chemically alter biological molecules. Formaldehyde creates crosslinks between proteins and between proteins and nucleic acids, helping preserve the physical structure of cells but damaging or obscuring molecular information. Paraffin embedding adds another obstacle because the wax must be removed before tissue can be processed. RNA is particularly vulnerable. Unlike DNA, which is relatively stable, RNA molecules are fragile and can fragment or become chemically modified during fixation and storage. These changes have made it difficult to apply single-cell RNA sequencing, or scRNA-seq, to older FFPE samples.

ScRNA-seq has transformed cell biology by allowing researchers to examine gene activity one cell at a time. In a conventional tissue analysis, RNA from thousands or millions of cells may be mixed together, producing an average molecular profile that can conceal important differences. Single-cell sequencing preserves those distinctions. It can reveal which genes are active in individual cells, identify rare cell populations and show how neighboring cell types respond differently to disease, aging or treatment. Because RNA reflects which genetic instructions a cell is using, scRNA-seq provides a molecular snapshot of cell identity and function rather than merely showing the cell’s appearance under a microscope.

Earlier methods for analyzing FFPE tissue often focused on isolating cell nuclei. Nuclei are more resistant to the damage caused by preservation and contain genetic material that can still be sequenced. However, isolating only the nucleus removes the surrounding cytoplasm, where substantial amounts of RNA and other molecular information are found. This loss can reduce the number of detectable genes and make it harder to distinguish closely related cell states. It can also bias the results toward cell types whose nuclei survive the isolation procedure particularly well, leaving researchers with an incomplete representation of the original tissue.

The Vanderbilt team built on an intact-cell dissociation procedure developed by Simmons to recover more complete cells from FFPE samples. The method is designed to release whole cells from preserved tissue while minimizing the loss of cellular material outside the nucleus. Once recovered, the cells can be processed for scRNA-seq. In practical terms, this means that sequencing libraries can contain RNA from both the nucleus and the cytoplasm, increasing the amount of information available from each cell. The researchers reported that their procedure improved cell recovery and gene detection, two critical measures of performance in single-cell experiments.

The study tested the approach in samples from the colon and thymus, tissues with markedly different cellular structures. The colon contains relatively large epithelial cells lining its surface, along with other cell types embedded in a complex tissue architecture. These cells contain substantial cytoplasmic material beyond the nucleus, so recovering them intact can preserve information that nuclear sequencing would miss. In the colon samples, the new procedure produced a clear improvement in whole-cell recovery and gene detection. It also helped recover cell populations that are often underrepresented in single-cell experiments, offering a more complete view of the tissue’s cellular composition.

The results were less striking in thymus tissue, which contains many smaller immune cells. These cells have less cytoplasmic material outside the nucleus, meaning that the advantage of preserving the entire cell may be more limited. The contrast between the two tissue types suggests that intact-cell dissociation will not provide the same benefit for every archived sample. Instead, its value may depend on cell size, tissue structure, the extent of fixation damage and the physical interactions holding cells together. The findings also show why sample-specific optimization will remain important as researchers attempt to apply molecular technologies to historical specimens.

The potential scientific payoff extends beyond improving a laboratory protocol. Researchers could use archived tumors to compare the individual cells of patients who responded well to a therapy with those of patients whose disease progressed. They could investigate whether rare cell populations were associated with relapse, determine how immune and epithelial cells interacted within diseased tissue, or identify molecular signatures linked to survival. Because many FFPE samples are accompanied by detailed clinical records, such studies could connect gene activity at the cellular level with real-world outcomes. That combination could help reveal how diseases develop, explain why treatments work for some patients but not others, and identify biomarkers or therapeutic targets that would be difficult to discover from newly collected samples alone.

The work also highlights a broader shift in biomedical research: technologies once designed for fresh tissue are increasingly being adapted to the preserved materials already stored in hospitals worldwide. The Vanderbilt researchers caution that FFPE samples still present technical limitations, including RNA degradation and preservation-induced chemical changes, and that the thymus results demonstrate the method’s boundaries. Nevertheless, by recovering intact cells rather than only nuclei, the procedure opens a path toward turning decades of largely inaccessible pathology material into high-resolution molecular maps. The study, published in Cellular and Molecular Gastroenterology and Hepatology, suggests that the next generation of discoveries may come not only from collecting new samples, but also from looking again at the vast biological record already sitting in medical archives.

Subject of Research: Intact-cell recovery and single-cell RNA sequencing of formalin-fixed, paraffin-embedded human tissue

Article Title: Intact Cell Dissociation of FFPE Colon Tissue Enhances Cell Recovery and Gene Detection in scRNA-seq

News Publication Date: 13-Aug-2026

Web References: https://doi.org/10.1016/j.jcmgh.2026.101863; https://ncbi.nlm.nih.gov/geo/ (dataset accession: GSE338505)

References: Cellular and Molecular Gastroenterology and Hepatology; DOI: 10.1016/j.jcmgh.2026.101863

Image Credits: Vanderbilt University; Ken Lau, Vanderbilt University

Keywords: single-cell RNA sequencing, scRNA-seq, FFPE tissue, formalin-fixed paraffin-embedded tissue, intact cell dissociation, RNA sequencing, cell biology, tissue biology, colon tissue, thymus, gene expression, biomedical research, pathology archives

FFPE tissues have historically been a mainstay in medical diagnostics, particularly in oncology, due to their excellent histological preservation and ease of storage. However, their chemical fixation process introduces significant technical complications for molecular analyses, especially for WGS. The formalin fixation leads to DNA fragmentation, cross-linking, and chemical modifications that degrade nucleic acid quality, complicating sequencing efforts. Until now, this has limited expansive genomic analyses primarily to fresh or frozen tissues, which are often not readily available in clinical workflows, thus limiting retrospective studies and the utility of vast FFPE archives.

The innovative approach articulated in this study overcomes the conventional pitfalls by implementing an optimized sequencing pipeline that enhances DNA extraction, library preparation, and bioinformatic processing tailored specifically for FFPE-derived material. At its core, the methodology incorporates refined DNA repair protocols that mitigate formalin-induced damage, coupled with enhanced enzymatic steps that improve library complexity and uniformity of coverage across the genome. Furthermore, advanced computational algorithms correct for FFPE-specific artifacts and ensure high fidelity variant calling, pushing the analytical quality near that of fresh-frozen counterparts.

This pioneering technique holds profound clinical implications. Whole genome sequencing offers an unbiased, comprehensive view of the cancer genome, detecting not only point mutations but also structural rearrangements, copy number alterations, and complex mutational signatures. With the ability to reliably perform WGS on FFPE specimens, clinicians and researchers can now access extensive retrospective cohorts of archival tumor material, accelerating biomarker discovery, therapeutic target identification, and unraveling tumor evolution dynamics in a manner previously constrained by sample quality.

The research team conducted extensive validation studies encompassing a diverse set of clinical FFPE samples from multiple cancer types, benchmarked against matched frozen tissues. The results demonstrated remarkable concordance in mutation detection rates, coverage uniformity, and structural variant identification, highlighting the robustness and reproducibility of the technique across pathological contexts. Importantly, the workflow exhibits scalable throughput and compatibility with standard clinical laboratory instrumentation, facilitating rapid integration into oncology diagnostics pipelines.

One of the key technical triumphs lies in addressing the challenges of PCR amplification bias inherent in fragmented FFPE DNA. The optimized library preparation protocols utilize unique molecular identifiers (UMIs) to tag individual DNA molecules prior to amplification. This strategy minimizes false positives caused by PCR duplicates and enables accurate molecular counting to quantify variant allele fractions sensitively. The study’s bioinformatics framework leverages UMI-aware algorithms to refine variant calling, markedly enhancing specificity without compromising sensitivity.

Beyond variant detection, the comprehensive genomic profiles generated from these FFPE specimens enable the delineation of mutational processes operative in tumorigenesis. Analyzing mutational signatures gleaned from high-quality WGS data allows researchers to infer carcinogenic exposures and DNA repair deficiencies that may inform clinical decision-making. This capability underscores the transformative potential of integrating WGS from FFPE samples into routine cancer management to guide therapeutic regimens tailored to each patient’s unique tumor biology.

The implications extend into clinical trial design as well, where archival FFPE specimens often represent the primary source material for biomarker stratification and correlative studies. The presented methodology affords investigators unprecedented access to rich genomic data sets from retrospective cohorts, enhancing biomarker validation and accelerating the discovery of novel predictive markers. This paves the way for more efficient trial designs with refined patient selection criteria based on comprehensive genomic profiling.

From a practical standpoint, the entire workflow is optimized for cost-effectiveness and turnaround time, carefully tailored to meet clinical laboratory standards. The streamlined DNA extraction and repair processes reduce sample input requirements, preserving precious archival materials. Moreover, the bioinformatic pipelines are implemented with high automation to facilitate rapid data processing and interpretation, aligning with the demands of clinical oncology settings where timely results are critical.

The study’s authors emphasize the importance of standardization and quality control in adopting FFPE-based WGS in clinical environments. They propose a set of benchmarking metrics and validation criteria to ensure consistent data quality across laboratories, addressing reproducibility, sensitivity thresholds, and reporting standards. This call for harmonization will be pivotal as more institutions consider integrating this powerful technology into cancer diagnostics and research.

Looking ahead, this innovation sets the stage for a paradigm shift in precision oncology by democratizing access to comprehensive genomic sequencing for the vast majority of clinical specimens. The ability to efficiently harness archival FFPE tissue repositories promises to catalyze discoveries linking genotype to phenotype, resistance mechanisms, and tumor heterogeneity. The data generated will empower clinicians to make better-informed therapeutic decisions, ultimately improving patient outcomes across cancer types.

Furthermore, the broader scientific community stands to benefit from this advancement given that FFPE samples constitute the most abundant human tissue resource worldwide. Large-scale cancer genomics projects can now incorporate FFPE-derived data sets, enriching public databases and enhancing the robustness of meta-analyses. This will facilitate the identification of rare driver mutations and complex genomic events previously underrepresented due to technical constraints.

The novel protocols detailed also open opportunities for integrating multi-omic analyses with FFPE samples, combining genomic data with transcriptomic and epigenomic profiling to provide a holistic molecular portrait of tumors. These integrative approaches promise to unveil deeper insights into tumor biology and uncover novel therapeutic vulnerabilities, underscoring the transformative impact of this technical leap in molecular pathology.

Ultimately, the development heralded by Domenico et al. signifies an important milestone in molecular oncology and diagnostic genomics. By surmounting the technical hurdles of FFPE tissue sequencing, it enables a new era of genomic medicine grounded in the extensive historical repositories of tissue samples available in virtually every pathology archive worldwide. This will accelerate both translational discoveries and personalized treatment strategies, representing a major step toward truly individualized cancer care.

This breakthrough aligns with broader initiatives to implement genomic medicine at scale in routine oncology practice. As sequencing costs continue to decline and bioinformatics capabilities expand, the ability to perform WGS reliably from FFPE samples ensures that nearly every cancer patient can benefit from comprehensive genomic insights irrespective of sample type. This democratization of cutting-edge molecular profiling is a critical enabler of precision oncology’s promise.

Such pioneering work exemplifies how innovative engineering and computational biology can unlock biological information long trapped within challenging specimen types. By bridging the gap between archived pathology material and next-generation sequencing technologies, these advances provide the clinical and scientific communities with powerful new tools to investigate cancer genetics comprehensively. The ripple effects will be felt across research, diagnostics, and patient care for years to come.

In summary, the methodology introduced for enabling whole genome sequencing analysis directly from FFPE specimens represents a transformative technological advance with wide-reaching implications for clinical oncology and cancer research. This work not only enhances the utility of the vast FFPE tissue repositories but also integrates seamlessly into clinical and research workflows, thereby accelerating precision medicine efforts and contributing to improved cancer diagnostics and therapeutics globally.

Subject of Research: Whole genome sequencing analysis of formalin-fixed paraffin-embedded (FFPE) specimens in clinical oncology.

Article Title: Enabling whole genome sequencing analysis from FFPE specimens in clinical oncology.

Article References:
Domenico, D., Gundem, G., Levine, M.F. et al. Enabling whole genome sequencing analysis from FFPE specimens in clinical oncology. Nat Commun 16, 10649 (2025). https://doi.org/10.1038/s41467-025-65654-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65654-7

Bladder cancer remains a formidable clinical challenge due to its heterogeneous nature and variable response to therapy. Precise molecular characterization of tumor samples is crucial for tailored treatment strategies. The FRS2 gene, implicated in multiple signaling pathways that regulate cellular proliferation and differentiation, has recently emerged as a key biomarker. Detecting copy number variations of FRS2 can yield critical insights into tumor biology and guide therapeutic decisions. However, conventional detection methods, such as fluorescence in situ hybridization (FISH), although specific, often lack the quantitative resolution and throughput necessary for routine clinical application.

The research team embarked on designing a ddPCR assay, capitalizing on its ability to provide absolute quantification of nucleic acids without reference to standard curves. Using FFPE bladder cancer samples, which are notoriously challenging due to DNA degradation and cross-linking, the assay was validated for sensitivity, specificity, and dynamic range. Employing FRS2 as the target gene and RPP30 as a single-copy reference gene, the researchers optimized primer and probe sets to enable duplex detection within a single reaction, thus improving assay efficiency and reducing sample consumption.

A critical milestone was the assay’s performance in discriminating positive from negative droplets. One-dimensional fluorescence amplitude plots demonstrated distinct separation between droplets containing the FRS2 and RPP30 sequences and those without target DNA, underscoring the assay’s robustness. This clear demarcation is essential for accurate quantification, as ambiguous droplet signals can confound data interpretation and undermine reliability.

Precision studies revealed excellent repeatability, with intra-assay coefficients of variation (CV) ranging from 2.58% to 3.75% across tested DNA input amounts. Inter-assay variability was equally impressive, registering CVs below 4%, affirming the method’s reproducibility. Such consistency is paramount in clinical settings, where diagnostic assays must deliver reliable results across multiple runs and laboratories.

Importantly, the minimal input DNA requirement was determined to be as low as 2 nanograms, a remarkably low threshold given the limited availability of tumor DNA in clinical samples. The assay maintained linearity across a broad concentration range, with correlation coefficients (R²) exceeding 0.99, indicating its suitability for both low and high copy number detection, inclusive of amplification events frequently observed in oncogenes.

Validation against the gold-standard FISH technique showcased the ddPCR assay’s impeccable accuracy. Achieving 100% sensitivity and specificity, along with a perfect kappa value of 1.0, the ddPCR method matched FISH in identifying true positive and negative cases without false results. This equivalence, combined with the advantages of ddPCR in throughput and quantitative output, suggests the assay’s potential to supplant or complement traditional cytogenetic approaches.

The duplex format of the assay, which simultaneously quantifies FRS2 and the reference gene RPP30 within the same tube, eliminates potential inter-sample variability. By normalizing the target gene copy number to a stable reference, the assay mitigates biases arising from DNA quality and quantity fluctuations, thus enhancing confidence in copy number calls, particularly in clinical samples where DNA degradation is common.

Extending beyond technical validation, the assay presents promising applications in bladder cancer diagnosis, stratification, and treatment monitoring. Quantifying FRS2 gene dosage could identify patients harboring gene amplifications associated with aggressive tumor behavior or resistance to conventional therapies. Integrating this molecular metric into clinical workflows may pave the way for personalized medicine approaches, improving patient outcomes through more precise risk assessment.

Furthermore, the utilization of FFPE samples in this assay reflects real-world conditions, as archival tissue specimens are often the primary resource for molecular diagnostics. Overcoming challenges associated with FFPE-derived DNA, such as fragmentation and chemical modifications, demonstrates the assay’s practical relevance and potential for widespread adoption in pathology laboratories.

The deployment of ddPCR technology in this context underscores its versatility and transformative impact on cancer genomics. By enabling absolute quantification without the need for standard curves and offering high sensitivity even with minimal and compromised DNA inputs, ddPCR stands out as a superior alternative to quantitative PCR and other amplification-based methods.

In synthesis, the reported ddPCR assay embodies a significant leap forward in bladder cancer molecular diagnostics. Its combination of analytical rigor, operational efficiency, and clinical applicability embodies the changing landscape of cancer genomics, where precision and scalability are paramount. The meticulous development and validation process ensure that this assay can serve as a reliable tool for researchers and clinicians alike, facilitating nuanced genetic profiling essential for next-generation oncology.

As precision medicine continues to evolve, such innovations are critical in bridging the gap between laboratory research and patient-centered care. The ability to accurately and reproducibly measure gene copy numbers in challenging FFPE samples could unlock new biomarkers and therapeutic targets, ultimately translating into more tailored and effective treatments for bladder cancer patients worldwide.

The implications of this technology extend beyond bladder cancer, offering a methodological blueprint for similar assays targeting diverse genetic alterations across various malignancies. By refining molecular assays to cope with the practical constraints of clinical samples, ddPCR paves the way for broader implementation of genomic diagnostics and personalized oncology.

In conclusion, the ddPCR assay for FRS2 gene copy number quantification epitomizes the synthesis of innovative molecular techniques with clinical imperatives. Its demonstrated precision, sensitivity, and operational advantages position it as a frontrunner in the quest for robust cancer biomarker assays, setting a new standard for genetic analysis in FFPE tissue specimens.

Subject of Research: Development and validation of a droplet digital PCR assay for FRS2 gene copy number quantification in FFPE bladder cancer tissue samples.

Article Title: Droplet digital PCR assay for precise determination of FRS2 gene copy number in bladder cancer.

Article References:
Li, J., Liang, J., Xu, Y. et al. Droplet digital PCR assay for precise determination of FRS2 gene copy number in bladder cancer. BMC Cancer 25, 1211 (2025). https://doi.org/10.1186/s12885-025-14611-0

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14611-0